Cargando…

COVID-19 Mortality: The Culprit May Not Be Proton Pump Inhibitors

Detalles Bibliográficos
Autores principales:	Duan, Zhihui, Zhou, Shengyun, Sun, Xiaofang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the AGA Institute 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358103/ https://www.ncbi.nlm.nih.gov/pubmed/34391925 http://dx.doi.org/10.1016/j.cgh.2021.08.013

Ejemplares similares

Liver injury in COVID-19 – The culprit may not be COVID-19!
por: Singh, Aditya, et al.
Publicado: (2021)

Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?
por: Alsalahi, Omran, et al.
Publicado: (2015)

Increased Proton Pump Inhibitors−Induced Mortality Risk in Hemodialysis Patients
por: Sertorio, Jonas T., et al.
Publicado: (2018)

An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19
por: Homolak, Jan, et al.
Publicado: (2021)

The dilemma in the management of suspected upper GI bleeding in patients with COVID-19 pneumonia
por: Duan, Zhihui, et al.
Publicado: (2020)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

Proton-pump inhibitors should be strictly prescribed in clinic
por: Yang, Xuesong, et al.
Publicado: (2022)

COVID-19 and Comorbid Hypertension: Is ACE2 the Culprit?
por: Zhang, Ting, et al.
Publicado: (2020)

Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients
por: Zirk-Sadowski, Jan, et al.
Publicado: (2017)

Deprescribing in older people: helpful tools and proton pump inhibitors
Publicado: (2020)

Heparin-induced hyponatremia in COVID-19: A latent culprit!
por: Panda, Rajesh, et al.
Publicado: (2021)

Non-peer-reviewed data, effect measures, and meta-regression analysis on proton pump inhibitor use and COVID-19
por: Wu, Dan-Na, et al.
Publicado: (2022)

The costly case of proton-pump inhibitors: a single-center experience
por: Suresh Kumar, Vishnu Charan, et al.
Publicado: (2020)

Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease
por: Tariq, Muhammad Ali, et al.
Publicado: (2022)

The Necessity of Validated Questionnaires: Determining Accurate Responses to Proton Pump Inhibitor Use
por: Jung, Kee Wook
Publicado: (2012)

High or Nonhigh Doses of Proton Pump Inhibitors for Patients with Peptic Ulcer Bleeding?
por: Hsieh, Yu-Hsi, et al.
Publicado: (2013)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Reduced gastric acidity, proton pump inhibitors and increased severity of COVID-19 infections
por: Price, Elizabeth, et al.
Publicado: (2021)

Association with the actual blood group is the ONLY culprit in ABO and COVID-19 disease severity
por: Hajeer, Ali H., et al.
Publicado: (2023)

Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011)

Does Helicobacter pylori eradication or proton pump inhibitor use benefit gastroesophageal reflux disease?
por: Sakin, Yusuf Serdar, et al.
Publicado: (2015)

Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis
por: Savarino, Edoardo, et al.
Publicado: (2016)

Unintended effects of proton pump inhibitors (PPIs) in patients with glioblastoma (GBM): A double-edged sword
por: Castro, Michael P
Publicado: (2022)

Subacute cutaneous lupus erythematosus due to proton pump inhibitor intake: case report and literature review
por: Reich, Adam, et al.
Publicado: (2012)

Immune Thrombotic Thrombocytopenic Purpura in a Patient with Suspected COVID-19: Hydroxychloroquine Culprit or Just Happenstance?
por: Mir, Tajamul H.
Publicado: (2021)

The culprits behind a hyper-intense spleen
por: Gude, Dilip, et al.
Publicado: (2011)

Curcumin in Stevens-Johnsons Syndrome: Culprit or Bystander?
por: Irani, Carla, et al.
Publicado: (2009)

Cisatracurium degradation: Intravenous fluid warmer the culprit?
por: Khan, Rashid M, et al.
Publicado: (2015)

Multiple Cranial-Nerve Palsies: An Unusual Culprit
por: Shashikala, Turlapati Padmavathi, et al.
Publicado: (2018)

Do Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Really Have No Effect on the Gastric Emptying Rate?
por: Tomita, Toshihiko, et al.
Publicado: (2011)

Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak
por: Tanriverdi, Ozgur
Publicado: (2020)

Is hypomagnesemia associated with using proton pump inhibitors?
por: Yi, Joo-Hark, et al.
Publicado: (2016)

Rutin exerts antiulcer effect by inhibiting the gastric proton pump
por: Dubey, Shagun, et al.
Publicado: (2013)

Meta-analysis associates proton pump inhibitor use with higher pneumonia risk in cirrhotic patients: mining for “diamonds” in the coal
por: Tziatzios, Georgios, et al.
Publicado: (2020)

Proton pump inhibitors in the COVID-19 pandemic()
por: Sebastián Domingo, Juan J.
Publicado: (2021)

Our data may be misleading and underestimating COVID-19 mortality figures
por: Gupta, Harish, et al.
Publicado: (2020)

Do Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Really Have No Effect on the Gastric Emptying Rate?: Author's Reply
por: Nonaka, Takashi, et al.
Publicado: (2011)

Use of proton pump inhibitors are associated with higher mortality in hospitalized patients with COVID-19
por: Wu, Shengyong, et al.
Publicado: (2022)

Culprits for Retrosternal Deformation After Coronary Artery Bypass Surgery
por: Özhan, Abdulkerim, et al.
Publicado: (2022)

Human papillomavirus E5 protein, the undercover culprit of tumorigenesis
por: Hemmat, Nima, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_99m4bt4gi965aj3vrqo5hl20ec